Skip to content.

Endoceutics obtains CCAA protection and approval of sale transactions despite contestation of its main secured creditor

Date Closed

May 18, 2023

Lead Office



148.00 Million CAD

On September 26, 2022, Endoceutics has commenced proceedings in obtaining protection under the Companies' Creditors Arrangement Act (the “CCAA”) quickly, allowing Endoceutics to maintain sufficient liquidity to proceed with the restructuring without the need to seek interim financing. A Sale and Investment Solicitation Process was approved by the Court on December 7, 2022. On May 18, 2023, despite the contestation of the Debtors’ main secured creditor, the Court granted the Debtors’ motion and approved 2 sale transactions allowing the Debtors’ ongoing operations. 

Endoceutics is a private pharmaceutical company operating in the fields of women's health and hormone-sensitive cancer prevention and treatment. Endoceutics is actively committed to advancing basic sciences, clinical research and development, world-class manufacturing, and product commercialization worldwide. 

McCarthy Tétrault assisted Endoceutics with a team led by Alain Tardif which includes Philippe Leclerc (Business), Frédérique Drainville (Bankruptcy & Restructuring) and Alexandre Saulnier-Marceau (business).